Article
Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.
Hepatology (Baltimore, Md.) - 1 Apr 2016
Jiang De-Ke, Wu Xiaopan, Qian Ji, Ma Xiao-Pin, Yang Jingmin, Li Zhuo, Wang Runhua, Sun Li, Liu Fang, Zhang Pengyin, Zhu Xilin, Wu Jia, Chen Kangmei, Conran Carly, Zheng S Lilly, Lu Daru, Yu Long, Liu Ying, Xu Jianfeng
Abstract excerpt
UNLABELLED: Interferon (IFN)-α is a first-line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus-related hepatocellular carcinoma. We aimed to determine whether this variant is associated with the response to IFNα treatment for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.